Wealthfront Advisers LLC Increases Position in Merck & Co., Inc. $MRK

Wealthfront Advisers LLC increased its holdings in Merck & Co., Inc. (NYSE:MRK) by 2.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 317,659 shares of the company’s stock after purchasing an additional 6,380 shares during the quarter. Wealthfront Advisers LLC’s holdings in Merck & Co., Inc. were worth $40,819,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of MRK. Pinnbrook Capital Management LP boosted its stake in shares of Merck & Co., Inc. by 95.2% during the fourth quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock worth $2,450,000 after buying an additional 11,355 shares during the period. Cibc World Market Inc. increased its position in Merck & Co., Inc. by 32.6% in the 4th quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock valued at $137,022,000 after acquiring an additional 320,143 shares during the period. Handelsbanken Fonder AB increased its position in Merck & Co., Inc. by 13.9% in the 4th quarter. Handelsbanken Fonder AB now owns 1,843,042 shares of the company’s stock valued at $193,999,000 after acquiring an additional 224,752 shares during the period. Russell Investments Group Ltd. raised its stake in Merck & Co., Inc. by 2.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company’s stock valued at $331,931,000 after acquiring an additional 51,393 shares during the last quarter. Finally, Panagora Asset Management Inc. raised its stake in Merck & Co., Inc. by 410.5% during the 4th quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company’s stock valued at $74,255,000 after acquiring an additional 567,249 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive melanoma results strengthen the pipeline. Merck and Moderna reported positive Phase 3 topline results for intismeran autogene, an individualized neoantigen therapy used with KEYTRUDA in resected melanoma. The program could create a new growth opportunity and help extend KEYTRUDA’s commercial runway. Merck Surges on a Melanoma Win
• Positive Sentiment: A busy fall catalyst calendar is attracting investors. Upcoming FDA decisions, additional pipeline updates and a pivotal cancer-vaccine readout could materially influence expectations for Merck’s post-KEYTRUDA growth profile. What Would It Take to Get MRK Stock to $200?
• Positive Sentiment: Pipeline progress, new product launches and potential M&A are improving the long-term growth outlook and easing concerns about eventual KEYTRUDA revenue pressure. Merck Stock Hits New 52-Week High
• Positive Sentiment: Analysts have become more bullish. Wolfe Research raised its price target from $155 to $180 with an outperform rating, while Argus increased its target from $145 to $170 and upgraded the stock to buy. These revisions provide additional support for the recent advance.
• Neutral Sentiment: The cancer-vaccine opportunity remains uncertain. Reuters noted that evidence for broad use of the personalized therapy is still limited, with manufacturing, patient-selection and clinical-adoption challenges potentially affecting its commercial impact. How the Merck-Moderna Cancer Vaccine Works
• Negative Sentiment: Valuation and execution risks are increasing. After gaining roughly 19% over the past month and trading near its 52-week high, MRK is approaching analyst targets, leaving less room for disappointment. Investors will likely focus on whether upcoming approvals and trial results can justify further upside.

Insider Buying and Selling

In other news, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president owned 36,613 shares in the company, valued at $4,942,755. This trade represents a 21.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This trade represents a 50.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 228,238 shares of company stock valued at $29,977,783 in the last quarter. Corporate insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $153.21 on Thursday. The stock has a market capitalization of $378.00 billion, a price-to-earnings ratio of 122.57, a PEG ratio of 6.56 and a beta of 0.19. The business’s 50 day moving average is $130.39 and its two-hundred day moving average is $122.04. Merck & Co., Inc. has a 12-month low of $77.58 and a 12-month high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same period last year, the firm earned $2.13 EPS. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Wall Street Analysts Forecast Growth

MRK has been the topic of several analyst reports. Jefferies Financial Group downgraded Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. JPMorgan Chase & Co. upped their price target on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. UBS Group lifted their price objective on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Argus boosted their price objective on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Barclays upped their price objective on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $147.60.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.